News | May 31, 2021
Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The company does not expect this development to have any material impact on the current business operations
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Subscribe To Our Newsletter & Stay Updated
